|
- Adagrasib (oral route) - Side effects dosage - Mayo Clinic
Adagrasib is used to treat non-small cell lung cancer (NSCLC) that has spread in patients who have received at least one previous treatment and whose tumors have an abnormal KRAS G12C gene
- Adagrasib - Wikipedia
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer [1][2] Adagrasib is an inhibitor of G12C mutated KRAS GTPase [1]
- KRAZATI® (adagrasib)
KRAZATI® (adagrasib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a
Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C, locking it in its inactive state Adagrasib showed clinical activity and had an acceptable adverse-event profile
- label - Food and Drug Administration
Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream
- Adagrasib Uses, Side Effects Warnings - Drugs. com
Adagrasib is used when the cancer has spread to other parts of the body (metastatic), or cannot be removed by surgery Adagrasib can be used alone or in combination with other cancer drugs Adagrasib is sometimes given after other cancer treatments did not work or have stopped working
- Adagrasib - NCI - National Cancer Institute
This page contains brief information about adagrasib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
- Adagrasib (Krazati®) - OncoLink
Adagrasib is a type of targeted therapy that blocks a protein called KRAS G12C Adagrasib inhibits the activity of KRAS G12C in cells which stops tumor cells from reproducing
|
|
|